Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL6000438

CCC(c1ccncc1)c1ccc(Br)cc1.N

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 3/20 0.56
KMT2A Q03164 1/20 0.44
SLC6A2 P23975 5/20 0.42
SLC6A4 P31645 5/20 0.42
SLC6A3 Q01959 5/20 0.42
CHRM2 P08172 3/20 0.42
CHRM1 P11229 3/20 0.42
DRD1 P21728 3/20 0.42
HRH1 P35367 2/20 0.42
KCNH2 Q12809 2/20 0.42
HRH3 Q9Y5N1 2/20 0.42
HTR2A P28223 2/20 0.42
LMNA P02545 2/20 0.42
CYP2D6 P10635 2/20 0.42
NFKB1 P19838 1/20 0.42
THPO P40225 1/20 0.42
HIF1A Q16665 1/20 0.42
HTR2C P28335 1/20 0.42
SCN1A P35498 1/20 0.42
SCN2A Q99250 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7060140 0.85 HTR2A (0.52) CYP17A1SLC6A2SLC6A4SLC6A3CHRM2
SCHEMBL377276 0.85 CYP17A1 (0.63) CYP17A1SLC6A2SLC6A4SLC6A3LMNA
Ammonia Solution, Strong SCHEMBL5999950 0.82 CYP17A1 (0.57) CYP17A1KMT2ASLC6A2SLC6A4SLC6A3
Ammonia Solution, Strong SCHEMBL5999712 0.82 SLC6A3 (0.59) CYP17A1SLC6A2SLC6A4SLC6A3HRH1
Ammonia Solution, Strong SCHEMBL5999442 0.81 CYP17A1 (0.51) CYP17A1KMT2ASLC6A2SLC6A4SLC6A3
Ammonia Solution, Strong SCHEMBL5999471 0.81 SLC6A4 (0.44) SLC6A2SLC6A4SLC6A3CHRM2CHRM1
Ammonia Solution, Strong SCHEMBL5999953 0.81 CYP17A1 (0.56) CYP17A1SLC6A2SLC6A4SLC6A3S1PR1
Ammonia Solution, Strong SCHEMBL5999692 0.81 CYP19A1 (0.59) CYP17A1SLC6A2SLC6A4SLC6A3CHRM2
SCHEMBL17802362 0.79 HTR2A (0.63) SLC6A2SLC6A4SLC6A3CHRM2CHRM1
SCHEMBL123538 0.79 SLC6A3 (0.61) CYP17A1SLC6A2SLC6A4SLC6A3HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060058357-A1 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke K AND K BIOSCIENCE, INC. (US) 2006-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058357-A1 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke SIGMAR1, GRM1, GRIN2C CYP17A1 4384/4885KMT2A 760/4885SLC6A2 1494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.